in inflammation and fibrosis
Laurent Pharma is a late stage clinical biotech company focusing on developing treatments for complex conditions caused by an unbalanced immune-inflammatory response.
Targeting cell membrane lipid composition and fluidity as a new paradigm for regulating host defense and the inflammation process.
Laurent Pharma has completed two Phase 2 clinical studies with LAU-7b, a first-in-class proresolving drug candidate, in cystic fibrosis and COVID-19.
LAU-7b is an oral drug candidate that showed potential to regulate membrane lipids and exert inflammation-controlling, antifibrotic and antiviral properties.
News & Events
Laurent Pharma to participate to H.C. Wainwright 23rd Annual Global Investment Conference, September 13 – 15, 2021